Department of Urology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Urol Oncol. 2013 Nov;31(8):1539-45. doi: 10.1016/j.urolonc.2012.03.007. Epub 2012 Oct 22.
To investigate small ubiquitin-like modifier (SUMO)-specific protease 1 (SENP1) expression in human prostate cancer (CaP) cells and its prognostic value for CaP patients after radical prostatectomy (RP).
SENP1 expression in CaP cells was detected by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and Western blotting. By using immunohistochemistry coupled with the tissue microarray (TMA) technique, we examined SENP1 protein expression in 115 specimens of CaP, 19 prostatic intra-epithelial neoplasia (PIN) tissues, and 24 normal prostate tissues. Moreover, correlations between SENP1 protein expression, clinicopathologic features, and prognosis were statistically analyzed.
Three CaP cells, DU145, PC-3, and LNCaP had overexpression of SENP1 mRNA and protein, while the nontransformed immortalized prostate cell RWPE-1 had relatively weak SENP1 expression. Especially, DU145, a hormone-independent CaP cell line, showed higher transcriptional and translational level of SENP1 than the others. SENP1 protein expression correlated with some clinicopathologic parameters, such as pathologic stage, Gleason score, and biochemical recurrence (BCR). Positive SENP1 immunostaining in the CaP, PIN, and normal prostate tissue samples were 76.5%, 57.9%, and 4.2%, respectively. CaP patients undergoing RP with positive SENP1 expression were significantly associated with poor biochemical-free survival. Multivariate analysis indicated that SENP1 protein expression was an independent prognostic factor for BCR-free survival after RP.
This study confirmed the up-regulation of SENP1 mRNA and protein level in CaP cells. We suggested that SENP1 expression might contribute to the malignant progression of CaP. Importantly, SENP1 presented as a potential prognostic factor for BCR after RP.
研究小泛素样修饰物（SUMO）特异性蛋白酶 1（SENP1）在人前列腺癌（CaP）细胞中的表达及其在根治性前列腺切除术（RP）后 CaP 患者中的预后价值。
通过定量逆转录聚合酶链反应（qRT-PCR）和 Western blot 检测 CaP 细胞中 SENP1 的表达。采用免疫组织化学结合组织微阵列（TMA）技术，检测了 115 例 CaP、19 例前列腺上皮内瘤变（PIN）和 24 例正常前列腺组织中 SENP1 蛋白的表达。此外，还对 SENP1 蛋白表达与临床病理特征及预后的相关性进行了统计学分析。
三种 CaP 细胞 DU145、PC-3 和 LNCaP 均过度表达 SENP1 mRNA 和蛋白，而非转化的永生化前列腺细胞 RWPE-1 则表达较弱。特别是激素非依赖性 CaP 细胞系 DU145，其 SENP1 的转录和翻译水平均高于其他细胞。SENP1 蛋白表达与一些临床病理参数相关，如病理分期、Gleason 评分和生化复发（BCR）。在 CaP、PIN 和正常前列腺组织样本中，SENP1 免疫染色阳性率分别为 76.5%、57.9%和 4.2%。在接受 RP 的 CaP 患者中，SENP1 表达阳性者的生化无复发生存率明显较低。多变量分析表明，SENP1 蛋白表达是 RP 后 BCR 无复发生存的独立预后因素。
本研究证实了 CaP 细胞中 SENP1 mRNA 和蛋白水平的上调。我们认为，SENP1 表达可能有助于 CaP 的恶性进展。重要的是，SENP1 可作为 RP 后 BCR 的潜在预后因素。
Zotero 插件